Larvol Delta - Pierre-Fabre-Laboratories-and-Scorpion-Therapeutics-Announce-First-Patient-Dosed-in-Phase-III-Clinical-Trial-of-PFL241STX241-a-MutantSelective-Inhibitor-Intended-To-Treat-Locally-Advanced-or-Metastatic-NonSmall-Cell-Lung-Cancer

STX-241 - Scorpion Therap, Pierre Fabre

https://www.prnewswire.com/news-releases/pierre-fabre-laboratories-and-scorpion-therapeutics-announce-first-patient-dosed-in-phase-iii-clinical-trial-of-pfl-241stx-241-a-mutant-selective-inhibitor-intended-to-treat-locally-advanced-or-metastatic-non-small-cell-lung-ca-302269906.html

Oct 8, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next